



Innovative Science for a Healthier Planet

Q3 2017 Earnings Call

November 14, 2017



Cautionary Notes

FORWARD-LOOKING STATEMENTS


This presentation and oral statements accompanying this presentation contain forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as expected full year 2017 revenues and gross margin, including product and product segment revenues, anticipated future revenue, business growth, financial performance and product sales growth, the expected execution and announcement of commercial agreements, including the timing thereof and the expected impacts on year-end cash balance and 2017 revenues resulting therefrom, the anticipated introduction of sweetener and human nutrition products, including the timing thereof and expected business growth related thereto, the expected expansion of Biossance products into SEPHORA Canada and Sephora Brazil, including the timing thereof, anticipated future Biossance retail sales and margin, expected year-end product gross margin, anticipated fourth quarter 2017 free cash flow and year-end cash position, expected future cash generation, including the sources thereof, anticipated future product margins and profitability, anticipated improvements of Amyris's balance sheet, the expected funding and construction of the Brotas 2 production facility, and expectations regarding Amyris's financial and operational results and ability to achieve its business plan in 2017 and beyond, that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund operating and capital expenses, timing and execution risks associated with manufacturing, uncertainty regarding consummating potential transactions, including the timing thereof, and growth in sales, potential delays or failures in development, production and commercialization of products, risks related to Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's quarterly report on Form 10-Q filed on August 14, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as result of new information, future events, or otherwise.

NON-GAAP FINANCIAL INFORMATION

This presentation and oral statements accompanying this presentation contain both GAAP and non-GAAP financial information. Amyris considers non-GAAP information to be a helpful measure to assess its operational performance and for financial and operational decision-making. Where non-GAAP financial measures are presented in these slides or in oral statements accompanying this presentation, a presentation of the most directly comparable GAAP financial measure and a quantitative reconciliation between the non-GAAP financial measure and the most comparable GAAP financial measure may be found in the Financial overview slides of this presentation or in the news release distributed today, which is available at investors.amyris.com.


Anticipated Strong Finish for 2017- Full Year Comparison

Revenue (\$ in millions)




Anticipated Strong Finish for 2017- YTD Comparison

Revenue (\$ in millions)




Amyris Product Revenue

Revenue (\$ in millions)



Amyris Product Segment Growth

Revenue (\$ in millions)



(* Discontinued products excluded)



Debt at September 30, 2017

(in \$ millions)

Debt Instrument Type	Maturity Date	Rate	Payment Type	Sep-17	Dec-16
Stegodon senior secured loans	Oct-18	9.5%/10.5%	Cash	\$ 28.6	\$ 28.6
TOTAL R&D notes	Mar-18	12.0%	Cash	\$ 3.7	\$ 3.7
Tranche I convertible notes	Oct-18	10.0%	PIK	\$ 13.1	\$ 22.6
Tranche II convertible notes	Jan-19	10.0%	PIK	\$ 12.1	\$ 11.0
6.5% convertible notes	May-19	6.5%	Cash	\$ 48.7	\$ 52.1
9.5% convertible notes	Apr-19	9.5%	Cash/stock	\$ 37.9	\$ 54.5
Shareholder loan	Dec-17	13.5%	Cash	\$ 2.0	\$ 31.0
Nomis Bay	May-18	18.0%	Cash/Shares	\$ -	\$ 10.0
Guanfu Loan	Dec-21	10.0%	Cash	\$ 25.0	\$ 25.0
Ginkgo Loan	May-17	13.5%	Cash	\$ -	\$ 8.5
Aprinova Joint Venture	Dec-29	5.0%	Cash	\$ 5.6	\$ 7.8
Brazil bank loans	Various	Various	Cash	\$ 11.7	\$ 13.3
Other loans	Various	Various	Cash	\$ -	\$ 0.1
Total Debt (ex-debt discount)				\$ 188.4	\$ 268.2
Unamortized debt discount				\$ (23.4)	\$ (41.2)
Total Debt (net of debt discount)				\$ 165.0	\$ 227.0

Total debt (ex debt discount)	\$ 188.4
Less: Debt mandatorily convertible to equity at maturity	\$ (21.2)
Total debt (before discount), excluding mandatory convertible debt	\$ 167.2



AMYRIS®